Results for this period
First quarter1 April 2026 to 30 June 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit.
The shaded area represents net assets as a proportion of total assets. It is calculated from the two amounts reported by the company.
In the Fine Chemicals Business, results benefited from increased demand for pharmaceutical intermediates and active pharmaceutical ingredients, spot orders for general-purpose chemicals for overseas markets, demand in the electronic materials field, and the launch of mass production for newly developed products. In the Flame Retardants Business, demand for flame retardants for plastics remained stable, while sales to overseas markets and selling price reviews were carried out. In the Health Support Business, results benefited from stable demand for pharmaceutical raw materials used in hemodialysis and a review of selling prices.
No applicable matters.
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 June 2026 |
| Net Sales | ¥3,147 million (YoY +18.4%) |
| Operating profit | ¥371 million (YoY +264.3%) |
| Ordinary income | ¥407 million (YoY +192.7%) |
| Profit attributable to owners of the parent | ¥289 million (YoY +232.4%) |
| Total assets | ¥16,022 million |
| Net assets | ¥11,702 million |
| Revision to Earnings Forecast | No change |
| Segment revenue | Fine Chemicals Business ¥1,530 million (YoY +39.9%), Flame Retardants Business ¥1,253 million (YoY +4.9%), Health Support Business ¥363 million (YoY -1.5%) |
| Segment profit | Fine Chemicals Business ¥393 million (YoY +53.8%), Flame Retardants Business ¥244 million (YoY +129.7%), Health Support Business ¥41 million (YoY +34.6%) |
| Depreciation and amortization | ¥106 million |
| Breakdown of extraordinary income (loss) | Extraordinary income Not disclosed / Extraordinary loss Loss on Disposal of Fixed Assets ¥0 million |
| Disclosure regarding the going concern assumption | No applicable matters. |
| Factors Behind Changes in Business Performance | In the Fine Chemicals Business, results benefited from increased demand for pharmaceutical intermediates and active pharmaceutical ingredients, spot orders for general-purpose chemicals for overseas markets, demand in the electronic materials field, and the launch of mass production for newly developed products. In the Flame Retardants Business, demand for flame retardants for plastics remained stable, while sales to overseas markets and selling price reviews were carried out. In the Health Support Business, results benefited from stable demand for pharmaceutical raw materials used in hemodialysis and a review of selling prices. |
Items this document does not state (21)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The Company actively pursued deeper transactions with customers. In the Fine Chemicals Business, results benefited from increased demand for pharmaceutical intermediates and active pharmaceutical ingredients, spot orders for general-purpose chemicals for overseas markets, demand in the electronic materials field, and the launch of mass production for newly developed products. In the Flame Retardants Business, demand remained stable, while sales to overseas markets continued and selling prices were reviewed. In the Health Support Business, demand for pharmaceutical raw materials used in hemodialysis remained stable, and selling prices were reviewed.